Barry J. Byrne

1. SCHOSER, Benedikt, ROBERTS, Mark, BYRNE, Barry J., SITARAMAN, Sheela, JIANG, Hai, LAFORET, Pascal, TOSCANO, Antonio, CASTELLI, Jeff, DIAZ-MANERA, Jordi, GOLDMAN, Mitchel P., et al., KORITNIK, Blaž (sodelavec pri raziskavi), et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL) : an international, randomised, double-blind, parallel-group, phase 3 trial. The Lancet neurology. 2021, vol. 20, iss. 12, str. 1027-1037. ISSN 1474-4422. DOI: 10.1016/S1474-4422(21)00331-8. [COBISS.SI-ID 86336259]

2. SCHOSER, Benedikt, KISHNANI, Priya S., BRATKOVIC, Drago, BYRNE, Barry J., CLAEYS, Kristl G., DIAZ-MANERA, Jordi, LAFORET, Pascal, ROBERTS, Mark, TOSCANO, Antonio, VAN DER PLOEG, Ans. T., et al., KORITNIK, Blaž (sodelavec pri raziskavi), et al. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease : a phase III open-label extension study (ATB200-07). Journal of neurology, Journal of neurology. 2024, vol. 271, str. 2810-2823. ISSN 1432-1459, ISSN 1432-1459. https://link.springer.com/article/10.1007/s00415-024-12236-0, DiRROS - Digitalni repozitorij raziskovalnih organizacij Slovenije, DOI: 10.1007/s00415-024-12236-0. [COBISS.SI-ID 230906883]

3. KISHNANI, Priya S., BYRNE, Barry J., CLAEYS, Kristl G., DIAZ-MANERA, Jordi, DIMACHKIE, Mazen M., KUSHLAF, Hani, MOZAFFAR, Tahseen, ROBERTS, Mark, SCHOSER, Benedikt, HUMMEL, Noemi, et al., KORITNIK, Blaž (sodelavec pri raziskavi), et al. Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease. Journal of patient-reported outcomes. 2024, vol. 8, article no. 132, str. 1-9. ISSN 2509-8020. https://jpro.springeropen.com/counter/pdf/10.1186/s41687-024-00805-w.pdf, DiRROS - Digitalni repozitorij raziskovalnih organizacij Slovenije, DOI: 10.1186/s41687-024-00805-w. [COBISS.SI-ID 230729987]